Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Antanil Plus
- Development stage
- Unknown
- Lead developer
- Ibn Sina Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Antanil Plus is an over-the-counter (OTC) fixed-dose combination antacid and antiflatulent medication developed and marketed by Ibn Sina Pharmaceuticals. It is formulated as chewable tablets and oral suspensions containing a combination of aluminium hydroxide, magnesium hydroxide, and simethicone. The antacid components, aluminium hydroxide and magnesium hydroxide, work synergistically to neutralize excess gastric acid, thereby relieving symptoms of heartburn, acid indigestion, sour stomach, and hyperacidity associated with peptic ulcers, gastritis, or gastroesophageal reflux disease (GERD). The combination of these two antacids balances their individual side effects on bowel motility, as aluminium hydroxide tends to cause constipation while magnesium hydroxide has a laxative effect. Simethicone, a physiologically inert surfactant, acts locally in the gastrointestinal tract to reduce the surface tension of gas bubbles, causing them to coalesce into larger bubbles that can be easily expelled, thereby relieving bloating, flatulence, and abdominal discomfort.
- Brand names
- Antanil Plus
- Other names
- Aluminium Hydroxide + Magnesium Hydroxide + SimethiconeAluminium Hydroxide, Magnesium Hydroxide, and SimethiconeAluminum Hydroxide + Magnesium Hydroxide + SimethiconeAluminum Hydroxide, Magnesium Hydroxide, and Simethicone
Beyond the preview
Go deeper on Antanil Plus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Antanil Plus.